ACAD Acadia Pharmaceuticals21.58-0.60 (-2.7%)
ACAD Acadia Pharmaceuticals23.07-2.36 (-9.3%)
Premarket Decliner
ACAD Acadia Pharmaceuticals25.43-0.98-3.7%
Premarket:23.00-2.43 (-9.6%)
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP)
Business WireThu, 24-Sep 7:00 AM
ACAD Acadia Pharmaceuticals26.75-0.54 (-2.0%)
ACAD Acadia Pharmaceuticals27.07-0.38 (-1.4%)